X

Stay Connected

Sign Up for Updates

 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Global COVID-19 vaccination matters now and for the future

By Anne McDonald Pritchett, PhD  |    November 29, 2021
Recently, I joined a panel at the Aspen Security Forum to discuss how we can best get vaccines in arms around the globe as we fight COVID-19. As I noted during my remarks, the world is more...   Read More

Guest post: Congress shouldn’t put future innovation at risk

By Guest Contributor  |    November 29, 2021
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The PhRMA blog welcomes guest...   Read More

What’s missing in the current drug pricing plan

By Brian Newell  |    November 23, 2021
A congressional forum looked at the role pharmacy benefit managers (PBMs) play in determining what patients pay out of pocket for prescription medicines. The forum provided an important reminder...   Read More

Insurance design barriers can impact patient adherence and can lead to poor health outcomes

By Cynthia Hicks  |    November 23, 2021
According to our inaugural Patient Experience Survey (PES), insurance design can jeopardize patients’ health due to access barriers to medicines.     Read More

ICYMI: PhRMA CEO speaks at STAT Summit about government price setting

By Andrew Powaleny  |    November 19, 2021
As part of the annual STAT Summit, PhRMA President and CEO Stephen J. Ubl recently spoke with STAT’s Matthew Herper to discuss the many unintended consequences expected from the latest drug...   Read More

Making medicines more affordable: Sharing savings at the pharmacy counter

By Emilie Signora  |    November 19, 2021
Common-sense reforms can help ensure everyone benefits from America’s engine of innovation and receives the care they need and deserve. In this series, we’re taking a closer look at PhRMA’s...   Read More

Preventing the next public health emergency: New evidence demonstrates need to address antimicrobial resistance

By Jocelyn Ulrich  |    November 18, 2021
COVID-19 is not the first pandemic caused by a novel strain of a virus affecting the upper respiratory tract. Over the past 100 years, pandemics have been caused by novel forms of influenza and...   Read More

Three things to know about so-called Medicare “negotiation” polling

By Tom Wilbur  |    November 18, 2021
As policymakers continue to push partisan drug pricing proposals, several polls misrepresenting voter opinion have been circulated to try and justify these flawed policies. These polls fail to...   Read More

In the current health care debate, Congress has lost sight of what matters to U.S. voters

By Debra DeShong  |    November 15, 2021
For months Congress has been debating massive changes to the nation’s social safety net, one of which is the highly popular Medicare prescription drug benefit. Unfortunately, much of what is being...   Read More

Announcing CAREs Grant Round 4

By Jackie McRae  |    November 12, 2021
Medicines can be critical to treating, managing, and sometimes curing illnesses, thereby offering an effective tool to improve health outcomes and reduce health disparities. However, numerous...   Read More

Making medicines more affordable: Modernizing Medicare

By Emilie Signora  |    November 11, 2021
Common-sense reforms can help ensure everyone benefits from America’s engine of innovation and receives the care they need and deserve. In this series, we’re taking a closer look at PhRMA’s...   Read More

Understanding breakthrough COVID-19 infections

By Richard Moscicki, M.D.  |    November 11, 2021
The biopharmaceutical industry continues to work around the clock to research, develop and manufacture vaccines and therapeutics to prevent and treat COVID-19. Already, we’ve made unprecedented...   Read More

Making Medicines More Affordable: Making coupons count

By Emilie Signora  |    November 5, 2021
Common-sense reforms can help ensure everyone benefits from America’s engine of innovation and receives the care they need and deserve. In this series, we’re taking a closer look at PhRMA’s...   Read More

What they are saying: Government price setting for medicines is not the answer

By Sarah Sutton  |    November 4, 2021
America’s biopharmaceutical companies continue to voice the dangers of current proposals in Washington that would allow the government to set prices for medicines. While it’s being called...   Read More

Fact Check: Do contract pharmacies help patients access 340B medicines? No.

By Nicole Longo  |    November 2, 2021
Over the years, there has been repeated acknowledgement that the 340B program is often not supporting the patients it was intended to help. (If you need a reminder, check out this piece in the New...   Read More

New report highlights importance of IP-intensive manufacturing industries to the U.S. economy

By Tim McClung  |    November 1, 2021
A new report from NDP Analytics showcases how innovation is the lifeblood of economic growth in the United States and that intellectual property (IP) protections are a crucial driver for high...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates